Abstract: OBJECTIVE To analyze the clinical relationship of calcium and phosphorus metabolism and parathyroid hormone levels in end-stage renal disease and provide scientific basis for the clinical treatment of end-stage renal disease. METHODS Clinical data of 86 patients with end-stage renal disease during Jan. 2010 - Dec. 2014 were retrospectively analyzed. Levels of intact parathyroid hormone (iPTH), serum creatinine (Scr), serum albumin (Alb), carbon dioxide combining power (CO₂CP), serum calcium and serum phosphate were observed by full-auto blood flow detector. Data were analyzed by software SPSS16.0. RESULTS Among the 86 patients with end-stage renal disease, 70 (81.4%) patients had hyperphosphatemia, 13 (15.11%) had lower serum calcium levels, 20 (23.26%) had higher serum calcium levels and 23 (26.74%) used calcium-containing phosphate binders or active vitamin D. The comparison of related indexes between patients with low serum calcium and those with normal serum calcium found that CO₂CP was significantly lower in the former than in the normal patients (P＜0.05). There were 15 (17.44%) patients with iPTH＜100 ng/L, most of whom had chronic renal tubular diseases. There were 40 (46.51%) patients with iPTH＞300 ng/L, most of whom had chronic glomerulonephritis. The respective analysis found the corrected serum calcium level was negatively correlated with iPTH. CONCLUSION Patients with end-stage renal disease had high incidence of hyperglycemia, and 50.00% of the patients had secondary increased hyperparathyroidism hormone levels. The serum calcium levels in patients after correction were associated with calcium-containing phosphate binders or active vitamin D, and it may have some association with acidosis.